We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+18.67%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.32B
AUM Growth
+$20.1M
Cap. Flow
+$138M
Cap. Flow %
10.43%
Top 10 Hldgs %
45.62%
Holding
85
New
8
Increased
16
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$19.7M
2
ALT icon
Altimmune
ALT
+$18.5M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$17.5M
4
SWTX
SpringWorks Therapeutics
SWTX
+$17.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.9M

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$54M
2
IGMS
IGM Biosciences
IGMS
+$10.8M
3
APLS
Apellis Pharmaceuticals
APLS
+$7.98M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$7.68M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$6.3M

Sector Composition

Rank Sector Weight
1 Healthcare 94.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TPTX
1
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$187M 14.13%
2,484,220
-1,215,780
-33% -$54M
DSGN icon
2
Design Therapeutics
DSGN
$788M
$77M 5.82%
5,500,000
+343,006
+7% +$4.63M
ERAS icon
3
Erasca
ERAS
$6.48B
$58.5M 4.42%
10,505,554
– –
RXDX
4
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$57.3M 4.33%
2,029,158
+205,714
+11% +$5.96M
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$43M 3.25%
950,000
-175,000
-16% -$7.98M
RVMD icon
6
Revolution Medicines
RVMD
$40.9B
$38.9M 2.94%
1,995,066
– –
BMEA icon
7
Biomea Fusion
BMEA
$88.2M
$38M 2.87%
3,170,872
– –
CCXI
8
DELISTED
ChemoCentryx, Inc.
CCXI
$35.3M 2.67%
1,425,000
+560,000
+65% +$12.3M
ALT icon
9
Altimmune
ALT
$580M
$35.1M 2.65%
+3,000,000
New +$18.5M
XBI icon
10
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$33.4M 2.53%
+450,000
New +$33.8M
MLTX icon
11
MoonLake Immunotherapeutics
MLTX
$1.62B
$30.9M 2.34%
6,065,001
+2,785,001
+85% +$17.5M
EWTX icon
12
Edgewise Therapeutics
EWTX
$4.42B
$30.6M 2.32%
3,850,000
-832,874
-18% -$6.3M
RNAM
13
DELISTED
Avidity Biosciences
RNAM
$29.2M 2.21%
2,012,115
– –
GLUE icon
14
Monte Rosa Therapeutics
GLUE
$1.92B
$28.9M 2.19%
2,993,717
-8,482
-0.3% -$85.2K
ACLX
15
DELISTED
Arcellx
ACLX
$27.6M 2.08%
+1,525,000
New +$19.7M
TARS icon
16
Tarsus Pharmaceuticals
TARS
$2.6B
$27.4M 2.07%
1,875,000
+499,018
+36% +$7.49M
JBIO
17
Jade Biosciences
JBIO
$1.22B
$27.1M 2.05%
49,448
-2,857
-5% -$1.36M
BHVN
18
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$26.9M 2.04%
184,894
+104,894
+131% +$13.4M
ACET icon
19
Adicet Bio
ACET
$84.7M
$26.3M 1.99%
112,500
+65,625
+140% +$14.4M
PHVS icon
20
Pharvaris
PHVS
$2.37B
$25.3M 1.91%
1,145,953
+461,065
+67% +$8.59M
FMTX
21
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$21.9M 1.65%
3,172,204
-896,147
-22% -$6.29M
HZNP
22
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$21.3M 1.61%
267,500
+167,500
+168% +$15.9M
TNGX icon
23
Tango Therapeutics
TNGX
$4.49B
$20.4M 1.54%
4,507,843
-391,342
-8% -$2.37M
MRTX
24
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$20.1M 1.52%
300,000
+250,000
+500% +$15.9M
AXNX
25
DELISTED
Axonics, Inc. Common Stock
AXNX
$18.3M 1.38%
322,240
– –
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q2 2022 Portfolio in Review

As of Q2 2022, Cormorant Asset Management held 85 positions worth $1.32B, up 1.5% from $1.3B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Cormorant Asset Management deployed $138M of net new capital in Q2 2022, opening 8 new positions and adding to 16 existing holdings. Its largest new stake was Arcellx: 1,525,000 shares worth $27.6M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Turning Point Therapeutics, Inc. Common Stock, an estimated $54M trimmed.

  • Cormorant Asset Management's largest Q2 2022 buy was Arcellx: 1,525,000 shares worth $27.6M.
  • Cormorant Asset Management added most to MoonLake Immunotherapeutics in Q2 2022, an estimated $17.5M increase.
  • Cormorant Asset Management's biggest Q2 2022 reduction was Turning Point Therapeutics, Inc. Common Stock, cutting an estimated $54M.
  • Cormorant Asset Management fully exited IGM Biosciences in Q2 2022, selling an estimated $10.8M.
  • Cormorant Asset Management's ten largest holdings make up 46% of its $1.32B portfolio in Q2 2022.
  • Cormorant Asset Management opened 8 new positions and closed 5 in Q2 2022.
  • Cormorant Asset Management's portfolio value rose 1.5% quarter-over-quarter to $1.32B.

Based on Cormorant Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.